New development comes after the FDA’s Mar. 8 Wegovy approval for patients at risk for heart attack and stroke.
Following the FDA’s Mar. 8 decision to approve semaglutide (Wegovy) as a preventive for stroke and heart disease in overweight individuals, the CMS announced last week that it will soon be covered under their Medicare Part D drug program as well, multiple news outlets report.
“This patient population has a higher risk of cardiovascular death, heart attack and stroke," John Sharretts, M.D., director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research said in an FDA news release. "Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health."
However, health plans may still require Medicare beneficiaries to undergo step therapy with other drugs before receiving a Wegovy prescription.
Marijane Hynes, M.D. is a clinical professor of Medicine at the George Washington Weight Loss Clinic in Washington, D.C. Almost half of the patients she serves are on Medicare or Medicaid.
“It is excellent that Medicare will cover Wegovy for CVD disease, as it will improve patient outcomes and help decrease cost and hospitalizations overall for patients with heart disease,” Hynes said.“However, this is secondary prevention, and Medicare needs to consider covering these medications for primary prevention when patients have obesity before they get heart disease.”
Without coverage, out of pocout-of-pocketket costs for Wegovy are around $1,400 a month, causing patients to seek cheaper options from Mexico and Canada. Gastric bypass surgeries are also extremely expensive without coverage – nearly $20,000 Hynes said.
Hynes also said that there is no “magic pill” or procedure that will make the weight melt away and stay away. She said there must be behavioral skills and an exercise regimen in place in addition to treatment.
There are also side effects that come along with Wegovy that patients should know about. Wegovy works by making fatty foods taste less appealing and can make patients sick if they decide to eat them after taking a dose.
“They're still injectable medications and someone has to be monitoring the patients and helping them through the side effects,” Hynes said.
Wegovy was first approved for chronic weight management in adults in June 2021. The approval was later expanded to include children ages 12 and older.
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
Comparing and Contrasting Continuous Glucose Monitors and Insulin Pumps
October 31st 2024The rising popularity of the continuous glucose monitor, which is not the same as an insulin pump, has been a huge advance in type 1 diabetes treatment, according to David Maahs, M.D., M.A., Ph.D., from Stanford University.
Read More